{"id":"NCT01850641","sponsor":"Kissei Pharmaceutical Co., Ltd.","briefTitle":"A Phase III Study of PA21 With Calcium Carbonate in Hemodialysis Patients With Hyperphosphatemia","officialTitle":null,"status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-04-29","primaryCompletion":"2013-12","completion":"2013-12-03","firstPosted":"2013-05-09","resultsPosted":"2018-10-09","lastUpdate":"2018-10-09"},"enrollment":35,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hemodialysis","Hyperphosphatemia"],"interventions":[{"type":"DRUG","name":"PA21","otherNames":[]}],"arms":[{"label":"PA21","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to investigate the safety and efficacy when administering PA21 with calcium carbonate in hemodialysis patients with hyperphosphatemia for 12 weeks.","primaryOutcome":{"measure":"Incidence of Adverse Events","timeFrame":"12 weeks","effectByArm":[{"arm":"PA21","deltaMin":28,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":35},"commonTop":["Diarrhoea","Nasopharyngitis","Dermatitis contact","Haemorrhage subcutaneous","Back pain"]}}